# EDGAR Filing Document

**Accession Number:** 0001388325
**File Stem:** 0001193125-23-001509
**Filing Date:** 2023-1
**Character Count:** 9148
**Document Hash:** 938eea5a65140f1f4a9ffbe0db21af6c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-001509.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001193125-23-001509

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bolt Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001641281
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 472804636
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92160
- **FILM NUMBER:** 23506718

**BUSINESS ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063
- **BUSINESS PHONE:** 650-665-9295

**MAIL ADDRESS:**
- **STREET 1:** 900 CHESAPEAKE DRIVE
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94063

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bolt Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150504
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Novo Holdings A/S
- **CENTRAL INDEX KEY:** 0001388325
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** TUBORG HAVNEVEJ 19
- **CITY:** HELLERUP
- **STATE:** G7
- **ZIP:** 2900
- **BUSINESS PHONE:** 45 8824 8824

**MAIL ADDRESS:**
- **STREET 1:** TUBORG HAVNEVEJ 19
- **CITY:** HELLERUP
- **STATE:** G7
- **ZIP:** 2900

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Novo A/S
- **DATE OF NAME CHANGE:** 20070130

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**SCHEDULE 13D** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No. 5)\*** 

------

## Bolt Biotherapeutics, Inc.
**(Name of Issuer)** 

**Common Stock, par value $0.00001 per share** 

**(Title of Class of Securities)** 

**097702 104** 

**(CUSIP Number)** 

**Barbara Fiorini Due** 

**Novo Holdings A/S** 

**Tuborg Havnevej 19** 

**Hellerup, Denmark DK-2900** 

**+45 3527 6592** 

***Copy to:***

**B. Shayne Kennedy, Esq.** 

**Latham & Watkins LLP** 

**650 Town Center Drive, 20<sup>th</sup> Floor** 

**Costa Mesa, CA 92626** 

**Telephone: (714) 540-1235** 

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)** 

**December 29, 2022** 

**(Date of Event which Requires Filing of this Statement)** 

------

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

------

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

------

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

CUSIP No.: 097702 104

1. &nbsp;&nbsp;&nbsp;&nbsp; Name of Reporting Person: &nbsp;&nbsp;&nbsp;&nbsp; Novo Holdings A/S

2. &nbsp;&nbsp;&nbsp;&nbsp; Check the Appropriate Box
if a Member of Group (See Instructions): &nbsp;&nbsp;&nbsp;&nbsp; (a) ☐ (b) ☐

3. &nbsp;&nbsp;&nbsp;&nbsp; SEC Use Only:

4. &nbsp;&nbsp;&nbsp;&nbsp; Source of Funds: &nbsp;&nbsp;&nbsp;&nbsp; WC

5. &nbsp;&nbsp;&nbsp;&nbsp; Check if Disclosure of
Legal Proceedings is Required Pursuant to Items 2(d) or 2(e): &nbsp;&nbsp;&nbsp;&nbsp; ☐

6. &nbsp;&nbsp;&nbsp;&nbsp; Citizenship or Place of
Organization: &nbsp;&nbsp;&nbsp;&nbsp; Denmark

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned By<br> Each<br> Reporting<br> Person<br> With: | &nbsp;&nbsp;&nbsp;&nbsp;7. | &nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power:<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned By<br> Each<br> Reporting<br> Person<br> With: | &nbsp;&nbsp;&nbsp;&nbsp;8. | &nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power:<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned By<br> Each<br> Reporting<br> Person<br> With: | &nbsp;&nbsp;&nbsp;&nbsp;9. | &nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power:<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |
| &nbsp;&nbsp;&nbsp; Number of<br> Shares<br> Beneficially <br> Owned By<br> Each<br> Reporting<br> Person<br> With: | 10. | &nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power:<br>&nbsp;&nbsp;&nbsp;&nbsp;0 |

---

11. &nbsp;&nbsp;&nbsp;&nbsp; Aggregate Amount Beneficially Owned by Each Reporting Person: &nbsp;&nbsp;&nbsp;&nbsp; 0

12. &nbsp;&nbsp;&nbsp;&nbsp; Check if the Aggregate
Amount in Row (11) Excludes Certain Shares: &nbsp;&nbsp;&nbsp;&nbsp; ☐

13. &nbsp;&nbsp;&nbsp;&nbsp; Percent of
Class Represented By Amount In Row (11): &nbsp;&nbsp;&nbsp;&nbsp; 0% (1)

14. &nbsp;&nbsp;&nbsp;&nbsp; Type of Reporting
Person: &nbsp;&nbsp;&nbsp;&nbsp; CO

(1) Based upon 37,660,893 shares of the Issuer's Common Stock outstanding as of November 3, 2022, as
reported in the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on November 10, 2022.

------

This amendment ("<u>Amendment No. 5</u>") amends the Schedule 13D originally filed with the SEC on February 11, 2021, as subsequently amended by Amendment No. 1 filed on November 22, 2021, Amendment No.2 filed on July 15, 2022, Amendment No. 3 filed on September 30, 2022, and Amendment No. 4 filed on December 28, 2022 (collectively, the "<u>Schedule</u>"), to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer's Common Stock in connection with sales. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule.

**Item 3.** **Source and Amount of Funds or Other Consideration** <br>

Item 3 amends and supplements Item 3 in the Schedule to reflect sales of the Issuer's stock since the filing of Amendment No. 4 on December 28, 2022, as follows:

On December 28, 2022, Novo Holdings A/S sold 719,590 shares at $1.2342 per share in the open market.

On December 29, 2022, Novo Holdings A/S sold 675,347 shares at $1.2698 per share in the open market.

On December 30, 2022, Novo Holdings A/S sold 1,139,528 shares at $1.2355 per share in the open market.

**Item 5.** **Interest in Securities of the Issuer** <br>

Item 5 amends and supplements Item 5 in the Schedule as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Novo Holdings A/S beneficially owns 0 shares of Common Stock (the " <u>Novo Shares</u> ") representing
approximately 0% of the Issuer's outstanding shares of Common Stock, based upon 37,660,893 shares of the Issuer's Common Stock outstanding as of November 3, 2022, as reported in the Issuer's 10-Q filed with the SEC on November 10, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has
the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Except as described herein, Novo Holdings A/S has not effected any transactions in the shares of the
Issuer's Common Stock and neither the Foundation nor any person listed on the Schedule I has effected any transactions in the Issuer's Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the
receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) As of December 29, 2022, Novo Holdings A/S ceased to be a beneficial owner of more than five percent of
the Issuer's Common Stock.

------

**SIGNATURE** 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Dated: January 4, 2023 | Novo Holdings A/S | Novo Holdings A/S |
|  | /s/ Barbara Fiorini Due | /s/ Barbara Fiorini Due |
|  | By: | Barbara Fiorini Due |
|  | Its: | General Counsel, Finance & Operations |

---